Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

被引：221

作者：

Verheijen, Remy B. ^{[1
]}

Yu, Huixin ^{[1
]}

Schellens, Jan H. M. ^{[2
,3
]}

Beijnen, Jos H. ^{[1
,3
]}

Steeghs, Neeltje ^{[2
]}

Huitema, Alwin D. R. ^{[1
,4
]}

机构：

[1] Netherlands Canc Inst Antoni van Leeuwenhoek, Dept Pharm & Pharmacol, Amsterdam, Netherlands

[2] Netherlands Canc Inst Antoni van Leeuwenhoek, Dept Med Oncol & Clin Pharmacol, Amsterdam, Netherlands

[3] Univ Utrecht, Dept Pharmaceut Sci, Utrecht, Netherlands

[4] Univ Utrecht, Med Ctr, Dept Clin Pharm, Utrecht, Netherlands

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 102卷 / 05期

关键词：

CHRONIC MYELOID-LEUKEMIA; RENAL-CELL CARCINOMA; EXPOSURE-RESPONSE ANALYSIS; IMATINIB PLASMA-LEVELS; PHASE-I SAFETY; CLINICAL-RESPONSE; JAPANESE PATIENTS; CANCER-PATIENTS; POPULATION PHARMACOKINETICS; DOSE-ESCALATION;

D O I：

10.1002/cpt.787

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable and clear relationships exist between exposure and treatment outcomes, fixed dosing is still standard practice. This review aims to summarize the available clinical pharmacokinetic and pharmacodynamic data into practical guidelines for individualized dosing of KIs through therapeutic drug monitoring (TDM). Additionally, we provide an overview of prospective TDM trials and discuss the future steps needed for further implementation of TDM of KIs.

引用

下载

页码：765 / 776

页数：12

共 50 条

[31] Role of therapeutic drug monitoring for protease inhibitors
John, L
Marra, F
Ensom, MHH
ANNALS OF PHARMACOTHERAPY, 2001, 35 (06) : 745 - 754
[32] Summary of the recommendations of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) on the therapeutic drug monitoring of tacrolimus
Lemaitre, Florian
Monchaud, Caroline
Woillard, Jean-Baptiste
Picard, Nicolas
Marquet, Pierre
THERAPIE, 2020, 75 (06): : 681 - 685
[33] Relevance of Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in Routine Clinical Practice: A Pilot Study
Escudero-Ortiz, Vanesa
Dominguez-Lenero, Vanessa
Catalan-Latorre, Ana
Rebollo-Liceaga, Joseba
Sureda, Manuel
PHARMACEUTICS, 2022, 14 (06)
[34] Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians
Alffenaar, Jan-Willem C.
Tiberi, Simon
Verbeeck, Roger K.
Heysell, Scott K.
Grobusch, Martin P.
CLINICAL INFECTIOUS DISEASES, 2017, 64 (01) : 104 - +
[35] PRACTICAL PROBLEMS OF THERAPEUTIC DRUG-MONITORING OF ANTICONVULSANTS
WALSON, PD
BRAIN & DEVELOPMENT, 1985, 7 (02): : 116 - 121
[36] Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy
Clarke, William A.
Chatelut, Etienne
Fotoohi, Alan K.
Larson, Richard A.
Martin, Jennifer H.
Mathijssen, Ron H. J.
Salamone, Salvatore J.
EUROPEAN JOURNAL OF CANCER, 2021, 157 : 428 - 440
[37] Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology
LoRusso, Patricia M.
Eder, Joseph Paul
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (07) : 1013 - 1028
[38] Barriers and opportunities for the clinical implementation of therapeutic drug monitoring in oncology
Menz, Bradley D.
Stocker, Sophie L.
Verougstraete, Nick
Kocic, Danijela
Galettis, Peter
Stove, Christophe P.
Reuter, Stephanie E.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (02) : 227 - 236
[39] On the possibility of low cost, adherent Therapeutic Drug Monitoring in Oncology
Dalla Marta, Silvia
Fornasaro, Stefano
Jaworska, Aleksandra
Toffoli, Giuseppe
Bonifacio, Alois
Sergo, Valter
BIOPHOTONICS: PHOTONIC SOLUTIONS FOR BETTER HEALTH CARE V, 2016, 9887
[40] Therapeutic drug monitoring-based clozapine dosing recommendations
Zernig, Gerald
Ng, Karen
Hiemke, Christoph
Saria, Alois
THERAPEUTIC DRUG MONITORING, 2007, 29 (01) : 130 - 131

← 1 2 3 4 5 →